Trial Profile
CUDC 427 in combination with standard capecitabine chemotherapy in patients with HER2-negative, advanced breast cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2012
Price :
$35
*
At a glance
- Drugs CUDC 427 (Primary) ; Antineoplastics; Capecitabine
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Dec 2012 New trial record